Discovery of Novel Tetrahydroquinoline Derivatives As Potent, Selective, and Orally Available AR Antagonists

Investigators discovered a novel tetrahydroquinoline derivative that demonstrated excellent oral bioavailability, indicating the potential to enhance in vivo efficacy and to serve as a promising therapeutic option for prostate cancer treatment.